Need to keep on prime of the science and politics driving biotech at the moment? Join to get our biotech publication in your inbox.
Good morning. As we speak, we’re listening to extra about President Trump’s “most-favored nation” plan for drug pricing, Recursion’s case for why the corporate laid off 20% of its employees, and extra.
HHS tries pushing pharma to the negotiating desk
The Trump administration is pressuring pharmaceutical corporations to barter drug costs all the way down to ranges seen in different rich nations, invoking a “most-favored nation” clause as leverage. Whereas trade executives await specifics on which medicine and worth targets may very well be in play, the Division of Well being and Human Companies is insisting corporations have already got the steering they want, STAT’s Daniel Payne experiences.
